» Articles » PMID: 37168049

Prognostic Role of Pretreatment Skeletal Muscle Index in Gastric Cancer Patients: A Meta-analysis

Overview
Specialty Oncology
Date 2023 May 11
PMID 37168049
Authors
Affiliations
Soon will be listed here.
Abstract

The association between pretreatment skeletal muscle index (SMI) and long-term survival of gastric cancer patients remains unclear up to now. The aim of this meta-analysis was to identify the prognostic value of pretreatment SMI in gastric cancer. The PubMed, EMBASE and Web of Science electronic databases were searched up to 5 June 2022 for relevant studies. The primary outcome was overall survival (OS) and the second outcomes were disease-free survival (DFS) and cancer-specific survival (CSS). The hazard ratios (HRs) and 95% confidence intervals (CIs) were combined to assess the relationship between pretreatment SMI and survival of gastric cancer patients. All statistical analyses were conducted by STATA 15.0 software. A total of 31 retrospective studies involving 12,434 patients were enrolled in this meta-analysis. The pooled results demonstrated that lower pretreatment was significantly associated with poorer OS (HR = 1.53, < 0.001). Besides, lower pretreatment SMI was also related with worse DFS (HR = 1.39, < 0.001) and CSS (HR = 1.96, < 0.001). Pretreatment SMI was significantly associated with prognosis of gastric cancer patients and lower SMI predicted worse survival. However, more prospective high-quality studies are still needed to verify our findings.

References
1.
Nose Y, Yamashita K, Takeoka T, Momose K, Saito T, Tanaka K . Perioperative Ghrelin Administration Attenuates Postoperative Skeletal Muscle Loss in Patients Undergoing Esophagectomy for Esophageal Cancer: Secondary Analysis of a Randomized Controlled Trial. Ann Surg Oncol. 2022; 29(6):3604-3612. DOI: 10.1245/s10434-022-11436-0. View

2.
Kim Y, Lee J, Jeong W, Kim S, Kim J, Hong J . Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. Gastric Cancer. 2020; 24(2):457-466. DOI: 10.1007/s10120-020-01124-x. View

3.
Zhuang C, Shen X, Zou H, Dong Q, Cai H, Chen X . EWGSOP2 versus EWGSOP1 for sarcopenia to predict prognosis in patients with gastric cancer after radical gastrectomy: Analysis from a large-scale prospective study. Clin Nutr. 2019; 39(7):2301-2310. DOI: 10.1016/j.clnu.2019.10.024. View

4.
Wang Y, Huang D, Xu W, Wang Y, Che G . Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio in Non-Small Cell Lung Cancer: A Meta-Analysis. Oncol Res Treat. 2019; 42(10):523-531. DOI: 10.1159/000501726. View

5.
Takagi K, Domagala P, Polak W, Buettner S, Wijnhoven B, IJzermans J . Prognostic significance of the controlling nutritional status (CONUT) score in patients undergoing gastrectomy for gastric cancer: a systematic review and meta-analysis. BMC Surg. 2019; 19(1):129. PMC: 6729085. DOI: 10.1186/s12893-019-0593-6. View